External Validation of the SERC Trial Population: Comparison with the Multicenter French Cohort, the Swedish and SENOMIC Trial Populations for Breast Cancer Patients with Sentinel Node Micro-Metastasis

Gilles Houvenaeghel¹, Houssein El Hajj¹, Julien Barrou¹, Monique Cohen¹, Pédro Raro², Jérémy De Troyer³, Pierre Gimbergues⁴, Christine Tunon de Lara⁵, Vivien Ceccato⁶, Véronique Vaini-Cowen⁷, Christelle Faure-Virelizier⁸, Frédéric Marchal⁹, Tristan Gauthier¹⁰, Eva Jouve¹¹, Pierrick Theret¹², Claudia Regis¹³, François Desmons¹⁴, Agnès Tallet^{1

15}, Jean-Marie Boher^{1

16}; The Serc Trial Group

Affiliations

¹ Department of Surgical Oncology, Institut Paoli Calmettes & CRCM & Aix Marseille Univ, 232 Bd de Sainte Marguerite, 13009 Marseille, France.
² Institut de Cancérologie de l'Ouest-Site Paul Papin, 15 rue André Boquel, 10059 49055 Angers CEDEX 02, France.
³ Polyclinique Urbain V, Chemin du Pont des Deux Eaux, 84000 Avignon, France.
⁴ Department of Surgical Oncology, Centre Jean Perrin, 58 rue Montalembert BP 392, 63011 Clermont Ferrand CEDEX, France.
⁵ Department of Surgical Oncology, Institut Bergonie, 229 cours de l'Argonne, 33076 Bordeaux CEDEX, France.
⁶ Department of Surgical Oncology, Institut Jean Godinot, 1 rue du Général Koenig, 51056 Reims, France.
⁷ Department of Gynecology and Obstetrics, Clinique du Parc Rambot 2, Avenue du Dr Aurientis, 13100 Aix en Provence, France.
⁸ Department of Surgical Oncology, Centre Léon Bérard, 28 rue Laennec, 69373 Lyon CEDEX 8, France.
⁹ Department of Surgical Oncology, Centre Alexis Vautrin, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.
¹⁰ Department of Gynecology and Obstetrics, Hopital de la mère et de l'enfant, 8 Avenue Dominique Larrey, 87000 Limoges, France.
¹¹ Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse, Oncopole, 1 Avenue Irène Joliot-Curie, 31059 Toulouse, France.
¹² Department of Gynecology and Obstetrics, CH Saint Quentin, 1 avenue Michel de l'Hospital, B.P. 608, 02321 Saint Quentin CEDEX, France.
¹³ Department of Senology, Centre Oscar Lambret, 3 rue F. Combemal, 59000 Lille, France.
¹⁴ Department of Gynecology and Obstetrics, GHM de Grenoble, La Clinique des Eaux Claires, 8 rue du Dr Calmette, 38028 Grenoble CEDEX 1, France.
¹⁵ Department of Radiotherapy, Institut Paoli Calmettes & CRCM & Aix Marseille Univ, 232 Bd Ste Marguerite, 13009 Marseille, France.
¹⁶ Department of Biostatistics, Institut Paoli Calmettes & CRCM & Aix Marseille Univ, 232 Bd Ste Marguerite, 13009 Marseille, France.

PMID: 33050650
PMCID: PMC7600229
DOI: 10.3390/cancers12102924

External Validation of the SERC Trial Population: Comparison with the Multicenter French Cohort, the Swedish and SENOMIC Trial Populations for Breast Cancer Patients with Sentinel Node Micro-Metastasis

Gilles Houvenaeghel et al. Cancers (Basel). 2020.

. 2020 Oct 11;12(10):2924.

doi: 10.3390/cancers12102924.

Authors

Affiliations

¹ Department of Surgical Oncology, Institut Paoli Calmettes & CRCM & Aix Marseille Univ, 232 Bd de Sainte Marguerite, 13009 Marseille, France.
² Institut de Cancérologie de l'Ouest-Site Paul Papin, 15 rue André Boquel, 10059 49055 Angers CEDEX 02, France.
³ Polyclinique Urbain V, Chemin du Pont des Deux Eaux, 84000 Avignon, France.
⁴ Department of Surgical Oncology, Centre Jean Perrin, 58 rue Montalembert BP 392, 63011 Clermont Ferrand CEDEX, France.
⁵ Department of Surgical Oncology, Institut Bergonie, 229 cours de l'Argonne, 33076 Bordeaux CEDEX, France.
⁶ Department of Surgical Oncology, Institut Jean Godinot, 1 rue du Général Koenig, 51056 Reims, France.
⁷ Department of Gynecology and Obstetrics, Clinique du Parc Rambot 2, Avenue du Dr Aurientis, 13100 Aix en Provence, France.
⁸ Department of Surgical Oncology, Centre Léon Bérard, 28 rue Laennec, 69373 Lyon CEDEX 8, France.
⁹ Department of Surgical Oncology, Centre Alexis Vautrin, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.
¹⁰ Department of Gynecology and Obstetrics, Hopital de la mère et de l'enfant, 8 Avenue Dominique Larrey, 87000 Limoges, France.
¹¹ Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse, Oncopole, 1 Avenue Irène Joliot-Curie, 31059 Toulouse, France.
¹² Department of Gynecology and Obstetrics, CH Saint Quentin, 1 avenue Michel de l'Hospital, B.P. 608, 02321 Saint Quentin CEDEX, France.
¹³ Department of Senology, Centre Oscar Lambret, 3 rue F. Combemal, 59000 Lille, France.
¹⁴ Department of Gynecology and Obstetrics, GHM de Grenoble, La Clinique des Eaux Claires, 8 rue du Dr Calmette, 38028 Grenoble CEDEX 1, France.
¹⁵ Department of Radiotherapy, Institut Paoli Calmettes & CRCM & Aix Marseille Univ, 232 Bd Ste Marguerite, 13009 Marseille, France.
¹⁶ Department of Biostatistics, Institut Paoli Calmettes & CRCM & Aix Marseille Univ, 232 Bd Ste Marguerite, 13009 Marseille, France.

PMID: 33050650
PMCID: PMC7600229
DOI: 10.3390/cancers12102924

Abstract

Many trials confirmed the safety of omitting axillary dissection in the selected patients treated for early breast cancer. The external validity of these trials is questionable. Our study aimed to evaluate the accuracy of the French population representativity in the SERC trial and the differences between these two populations as well as comparing the French and the Swedish populations (the SENOMIC trial population and the Swedish National Breast Cancer Registry (NKBC) cohort) of patients with sentinel node (SN) micro-metastasis. A higher rate of smaller tumors and grade 1 tumors was observed in the French cohort when compared to the SERC population. Our findings conclude that both French populations show similar characteristics. Positive non-sentinel node (NSN) rates at completion axillary lymph node dissection (ALND) were 10.28 % and 11.3 % in the SERC trial and French cohort, respectively (p = 0.5). The rate of grade 1 tumors was lower in the SENOMIC trial (16.2%) and in the NKBC cohort (17.4%) compared to the SERC trial population (27.3%) and the French cohort (34.4%). Our findings in addition to the previously demonstrated concordance between the SENOMIC trial and the NKBC populations imply that the results of both the SERC and the SENOMIC trials can be applied to both French and Swedish real populations.

Keywords: breast cancer; micro-metastases; sentinel node; trial.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Cited by

Omission of Completion Axillary Lymph Node Dissection for Patients with Breast Cancer Treated by Upfront Mastectomy and Sentinel Node Isolated Tumor Cells or Micrometastases.
Houvenaeghel G, Heinemann M, Classe JM, Bouteille C, Gimbergues P, Azuar AS, Martino M, Tallet A, Cohen M, de Nonneville A. Houvenaeghel G, et al. Cancers (Basel). 2024 Jul 26;16(15):2666. doi: 10.3390/cancers16152666. Cancers (Basel). 2024. PMID: 39123393 Free PMC article.
The prognostic significance of further axillary dissection for sentinel lymph node micrometastases in female breast cancer: A competing risk analysis using the SEER database.
Zhou Y, Pu S, Jiang S, Li D, Li S, Liu Y, Ren Y, Hao N. Zhou Y, et al. Front Oncol. 2022 Nov 17;12:1012646. doi: 10.3389/fonc.2022.1012646. eCollection 2022. Front Oncol. 2022. PMID: 36465338 Free PMC article.
Impact of Post-Mastectomy Radiation Therapy for Sentinel Lymph Node Micrometastases in Early-Stage Breast Cancer Patients.
Luo H, Yang OO, He JL, Lan T. Luo H, et al. Med Sci Monit. 2022 Jan 30;28:e933275. doi: 10.12659/MSM.933275. Med Sci Monit. 2022. PMID: 35094003 Free PMC article.
Early surgery versus conservative treatment in patients with traumatic intracerebral hematoma: a CENTER-TBI study.
van Erp IAM, van Essen TA, Lingsma H, Pisica D, Singh RD, van Dijck JTJM, Volovici V, Kolias A, Peppel LD, Heijenbrok-Kal M, Ribbers GM, Menon DK, Hutchinson P, Depreitere B, Steyerberg EW, Maas AIR, de Ruiter GCW, Peul WC; CENTER-TBI Investigators, Participants. van Erp IAM, et al. Acta Neurochir (Wien). 2023 Nov;165(11):3217-3227. doi: 10.1007/s00701-023-05797-y. Epub 2023 Sep 25. Acta Neurochir (Wien). 2023. PMID: 37747570 Free PMC article.
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial.
Houvenaeghel G, Cohen M, Raro P, De Troyer J, Gimbergues P, Tunon de Lara C, Ceccato V, Vaini-Cowen V, Faure-Virelizier C, Marchal F, Gauthier T, Jouve E, Theret P, Regis C, Gabelle P, Pernaut J, Del Piano F, D'Halluin G, Lantheaume S, Darai E, Beedassy B, Dhainaut-Speyer C, Martin X, Girard S, Villet R, Monrigal E, Hoyek T, Le Brun JF, Colombo PE, Tallet A, Boher JM; SERC trial group. Houvenaeghel G, et al. NPJ Breast Cancer. 2021 Oct 8;7(1):133. doi: 10.1038/s41523-021-00336-3. NPJ Breast Cancer. 2021. PMID: 34625562 Free PMC article.

See all "Cited by" articles

References

1. Rothwell P.M. External validity of randomised controlled trials: To whom do the results of this trial apply? Lancet. 2005;365:82–93. doi: 10.1016/S0140-6736(04)17670-8. - DOI - PubMed
1. Ford I., Norrie J. Pragmatic Trials. N. Engl. J. Med. 2016;375:454–463. doi: 10.1056/NEJMra1510059. - DOI - PubMed
1. De Boniface J., Frisell J., Andersson Y., Bergkvist L., Ahlgren J., Rydén L., Bagge R.O., Sund M., Johannson H., Lundstedt D., et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: The randomized controlled SENOMAC trial. BMC Cancer. 2017;17:379. doi: 10.1186/s12885-017-3361-y. - DOI - PMC - PubMed
1. Goyal A., Dodwell D. POSNOC: A Randomised Trial Looking at Axillary Treatment in Women with One or Two Sentinel Nodes with Macrometastases. Clin. Oncol. 2015;27:692–695. doi: 10.1016/j.clon.2015.07.005. - DOI - PubMed
1. Giuliano A.E. Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial. JAMA. 2011;305:569. doi: 10.1001/jama.2011.90. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

External Validation of the SERC Trial Population: Comparison with the Multicenter French Cohort, the Swedish and SENOMIC Trial Populations for Breast Cancer Patients with Sentinel Node Micro-Metastasis

Affiliations

External Validation of the SERC Trial Population: Comparison with the Multicenter French Cohort, the Swedish and SENOMIC Trial Populations for Breast Cancer Patients with Sentinel Node Micro-Metastasis

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources